|[July 07, 2014]
Sirtex Medical Inc. Announces 33 Percent Dose Sales Growth of SIR-Spheres® microspheres in Fourth Quarter
WOBURN, Mass. --(Business Wire)--
Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a
leading manufacturer of targeted, innovative liver cancer therapies,
announced dose sales of SIR-Spheres® microspheres grew 33
percent on a unit basis in the Americas region for the quarter ending
June 30, 2014, compared to the previous corresponding period.
"Our dedication to building a team focused on a comprehensive,
multidisciplinary approach to ensure optimal patient care has resulted
in an outstanding performance by the Americas region," said Mike
Mangano, president of Sirtex Medical, Inc. "Adoption rates for this very
important treatment option for patients continue to grow as we
anticipate the results of our landmark clinical study SIRFLOX in 2015."
Globally, Sirtex reported that dose sales of SIR-Spheres microspheres
grew 27.1 percent during the same period. Gilman Wong, Sirtex CEO, said,
"The successful implementation of our business strategy with appropriate
investment by the company in sales and marketing, manufacturing,
clinical studies and research should ensure Sirtex achieves its full
In the coming year, the Americas region willcontinue to focus on
patient and physician education and expansion strategies into other
regions supported by an emphasis on the company's clinical studies as
well as training and marketing efforts.
For more information, visit www.Sirtex.com
or find the latest updates on the SIR-Spheres microspheres Facebook (News - Alert) page
About Selective Internal Radiation Therapy using SIR-Spheres
Selective Internal Radiation Therapy (SIRT), also known as
radioembolization, is a proven technology for inoperable liver cancer
that delivers doses of radiation directly to the site of tumors. In a
minimally invasive treatment, millions of radioactive SIR-Spheres
microspheres are infused via a catheter into the liver where they
selectively target liver tumors with a dose of internal radiation up to
40 times higher than conventional radiotherapy, while sparing healthy
Clinical studies have confirmed that patients with metastatic colorectal
cancer treated with SIR-Spheres microspheres have response rates higher
than with other forms of treatment, resulting in increased life
expectancy, greater periods without tumor activity and improved quality
of life. SIRT has been found to shrink liver tumors more than
In the U.S., SIR-Spheres microspheres are indicated for the treatment of
unresectable metastatic liver tumors from primary colorectal cancer with
adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine).
SIR-Spheres microspheres are approved for use in Argentina, Brazil,
Australia, the European Union and several countries in Asia for the
treatment of unresectable liver tumors.
Available at more than 700 treatment centers, over 40,000 doses of
SIR-Spheres microspheres have been supplied worldwide.
For more information, visit www.sirtex.com.
SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres
[ Back To TMCnet.com's Homepage ]